Skip to content

Double-Blind, Placebo-Controlled Study for the Effect of Daily Ingestion of Yabukita green tea and Sun Rouge green tea on the Improvement of Blood Pressure and Eyestrain

Double-Blind, Placebo-Controlled Study for the Effect of Daily Ingestion of Yabukita green tea and Sun Rouge green tea on the Improvement of Blood Pressure and Eyestrain - The Effect of Daily Ingestion of the green tea on the improvement of Blood Pressure and Eyestrain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000018469
Enrollment
108
Registered
2015-07-29
Start date
2015-07-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Ingestion of Yabukita green tea daily for 12 weeks Ingestion of Sun Rouge green tea daily for 12 weeks Ingestion of barley tea for 12 weeks

Sponsors

Hokkaido Information University
Lead Sponsor
National Food Research Institute, National Agriculture and Food Research Organization
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects whose blood pressure meet either of the following criteria 1. Hospital SBP is 130 mmHg or more and less than 160 mmHg and DBP is less than 100 mmHg 2. Hospital DBP 80 mmHg or more and less than 100 mmHg and SBP is less than 160 mmHg 3. Home SBP is 125 mmHg or more and less than 155 mmHg and DBP is less than 95 mmHg 4. Home DBP is 75 mmHg or more and less than 95 mmHg and SBP is less than 155mmHg Subjects who agree to participate in the current study with a written informed consent

Exclusion criteria

Exclusion criteria: 1. Subjects who are under treatment and medication for hypertension 2. Subjects who are under treatment and medication for ocular disease (except for myopia, astigmatism, hyperopia, presbyopia, dry eye, and allergc conjunctival disease) or with serious ocular diseases. 3. Subjects who have a major ophthalmic surgical history such as cataract, glaucoma, refractive correction 4. Subjects with serious cerebrovascular, cardiac, hepatic, renal, and / or gastrointestinal diseases, or affected with an infectious disease which is required to report to the authorities 5. Subjects who have a major surgical history related to digestive system such as gastrectomy 6. Subjects with unusually high and/or low blood pressure or abnormal hematological data 7. Subjects with serious anemia 8. Pre- or post-menopausal subjects having complaints of obvious physical changes 9. Subjects who are at risk of having allergic reactions to drugs or foods (especially green tea) 10. Subjects who has high caffeine sensitivity 11. Subjects regularly take medicine, functional foods and/or supplements ( peptide, acetic acid, GABA, geniposidic acid, flavonoids, sesamin, chlorella, olive leaves, garlics, dietary fiber, tomatoes, folic acid, etc.) which would affect the blood pressure 12. Subjects regularly take medicine, functional foods and/or supplements (anthocyanin, lutein, astaxanthin, blueberry, beta-carotene, vitamin, DHA, EPA etc.) which would affect the visual fatigue 13. Heavy smokers, alcohol addicts or subjects with irregular lifestyle 14. Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to this study 15. Subjects who are pregnant or expected to be pregnant, or lactating during the study 16. Subjects who participate in other clinical trials within the last one month prior to the current clinical trial 17. Any other medical reasons judged by the principal investigator

Design outcomes

Primary

MeasureTime frame
systolic blood pressure and diastolic blood pressure (hospital blood pressure and home blood pressure), focus-adjustment function

Secondary

MeasureTime frame
VAS questionnaire for eyestrain symptoms, intraocular pressure, peripheral blood flow, MDA-LDL,TBARS,SOD,8-OHdG, hs-CRP,adiponectin, ADMA, blood RNA related to functional expression of the green tea-component, total homocysteine, LDL-C

Countries

Japan

Contacts

Public ContactDir. Prof. Jun NISHIHIRA, M.D., Ph.D.

Hokkaido Information University Center of Health Information Science

nishihira@do-johodai.ac.jp011-385-4430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026